Financials in USD. Standardized financial statements.
A compact view of how Collegium Pharmaceutical, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $780.57M | $631.45M | $566.77M | $463.93M | $276.87M | $310.02M | $296.70M | $280.41M | $28.48M | $1.71M |
| Revenue Growth? | +23.6% | +11.4% | +22.2% | +67.6% | -10.7% | +4.5% | +5.8% | +884.7% | +1564.3% | 0.0% |
| Cost of Revenue? | $317.31M | $254.10M | $240.60M | $254.44M | $126.25M | $130.18M | $193.66M | $165.68M | $2.60M | $213,000 |
| Gross Profit? | $463.26M | $377.34M | $326.17M | $209.49M | $150.62M | $179.84M | $103.04M | $114.74M | $25.88M | $1.50M |
| Gross Margin? | +59.3% | +59.8% | +57.5% | +45.2% | +54.4% | +58.0% | +34.7% | +40.9% | +90.9% | +87.6% |
| Operating Expenses? | $276.17M | $207.45M | $159.21M | $176.17M | $132.99M | $123.60M | $126.79M | $135.42M | $101.33M | $95.58M |
| Operating Income? | $187.08M | $169.90M | $166.96M | $33.32M | $17.63M | $56.23M | -$23.75M | -$20.68M | -$75.45M | -$94.08M |
| EBITDA? | $401.00M | $341.70M | $308.33M | $173.31M | $86.56M | $118.01M | -$6.33M | $91.91M | -$74.27M | -$93.43M |
| Income Before Tax | $92.62M | $98.57M | $75.73M | -$28.85M | -$3.37M | $27.58M | -$22.72M | -$39.13M | -$74.86M | -$94.18M |
| Income Tax Expense | $29.75M | $29.38M | $27.58M | -$3.85M | -$74.89M | $830,000 | $0 | $0 | $0 | $94,000 |
| Net Income? | $62.87M | $69.19M | $48.16M | -$25.00M | $71.52M | $26.75M | -$22.72M | -$39.13M | -$74.86M | -$94.18M |
| EPS? | $1.98 | $2.14 | $1.60 | $-0.74 | $2.05 | $0.78 | $-0.24 | $-1.19 | $-2.47 | $-3.88 |
| Diluted EPS? | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 | $0.76 | $-0.24 | $-1.19 | $-2.47 | $-3.88 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality